Skip to the page

Data / Drug companies / CSL Behring Lengnau AG

CSL Behring Lengnau AG: 12 products in the FDA NDC directory, labeler code 69911

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

CSL Behring Lengnau AG (labeler code 69911) lists 12 products in the FDA National Drug Code Directory, covering 2 finished drugs by generic name. By type: 12 plasma derivatives. Its main marketing category is biologics (BLA). The newest product started marketing on May 30, 2018.

The request: Watch CSL Behring Lengnau AG (FDA labeler code 69911): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
69911
Products in commercial distribution
12
Packages
12
Finished drugs by generic name
2
Prescription products
0
Over the counter products
0
Started marketing in the last 12 months
0
Earliest marketing start
March 4, 2016
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Biologics (BLA)12100%

Products by type

TypeProductsShare
Plasma derivatives12100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

DrugProductsCompanies listing it
Antihemophilic factor, human recombinant71
Coagulation factor ix recombinant human51

Dosage forms

Dosage formProductsShare
Kit12100%

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Idelvion69911-869KitBiologics (BLA)May 30, 2018
AFSTYLA Antihemophilic Factor (Recombinant), Single Chain69911-481KitBiologics (BLA)March 28, 2017
AFSTYLA Antihemophilic Factor (Recombinant), Single Chain69911-480KitBiologics (BLA)March 28, 2017
AFSTYLA Antihemophilic Factor (Recombinant), Single Chain69911-478KitBiologics (BLA)May 25, 2016
AFSTYLA Antihemophilic Factor (Recombinant), Single Chain69911-477KitBiologics (BLA)May 25, 2016
AFSTYLA Antihemophilic Factor (Recombinant), Single Chain69911-476KitBiologics (BLA)May 25, 2016
AFSTYLA Antihemophilic Factor (Recombinant), Single Chain69911-475KitBiologics (BLA)May 25, 2016
AFSTYLA Antihemophilic Factor (Recombinant), Single Chain69911-474KitBiologics (BLA)May 25, 2016
Idelvion69911-867KitBiologics (BLA)March 4, 2016
Idelvion69911-866KitBiologics (BLA)March 4, 2016
Idelvion69911-865KitBiologics (BLA)March 4, 2016
Idelvion69911-864KitBiologics (BLA)March 4, 2016

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.